ArticleTherapeutic advances in medical oncology2026
A clinical-molecular nomogram for predicting early recurrence following resection of initially unresectable colorectal liver metastases.
Article in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Factors Associated with the Timing of Liver Metastasis After Colorectal Cancer Surgery: A Retrospective Multicenter Study.Cancers · 2026Article
- Integrating perioperative inflammation and pathological invasiveness to predict recurrence after curative colorectal cancer surgery: a multicenter cohort study.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postoperative early recurrence (PER) remains a major challenge to long-term survival after successful conversion therapy and curative resection for initially unresectable colorectal liver metastases (CRLM). Existing prediction models rely heavily on clinicopathological parameters and lack molecular biomarkers, limiting their predictive accuracy. Objectives: To define the optimal recurrence-free survival (RFS) cutoff for PER and develop a comprehensive predictive nomogram incorporating molecular and clinical variables to predict PER in patients with initially unresectable CRLM who undergo curative resection following conversion therapy. Design: Retrospective cohort study. Methods: Clinicopathological and molecular data from 411 patients with initially unresectable CRLM undergoing curative resection after conversion therapy were analyzed. The minimum Results: PER was defined as recurrence within 4 months postoperatively. Independent predictors included dual preoperative positivity for CEA and CA19-9 (odds ratio (OR) = 2.437, Conclusion: We identified 4 months as the optimal RFS threshold for PER and proposed a novel nomogram integrating molecular and clinical factors for perioperative decision-making in patients with initially unresectable CRLM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.